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Abstract
Background: The pharmacological chaperones therapy is a promising approach to cure genetic diseases. It relies
on substrate competitors used at sub-inhibitory concentration which can be administered orally, reach difficult
tissues and have low cost. Clinical trials are currently carried out for Fabry disease, a lysosomal storage disorder
caused by inherited genetic mutations of alpha-galactosidase. Regrettably, not all genotypes respond to these
drugs.
Results: We collected the experimental data available in literature on the enzymatic activity of ninety-six missense
mutants of lysosomal alpha-galactosidase measured in the presence of pharmacological chaperones. We associated
with each mutation seven features derived from the analysis of 3D-structure of the enzyme, two features
associated with their thermo-dynamic stability and four features derived from sequence alone. Structural and
thermodynamic analysis explains why some mutants of human lysosomal alpha-galactosidase cannot be rescued
by pharmacological chaperones: approximately forty per cent of the non responsive cases examined can be
correctly associated with a negative prognostic feature. They include mutations occurring in the active site pocket,
mutations preventing disulphide bridge formation and severely destabilising mutations. Despite this finding,
prediction of mutations responsive to pharmacological chaperones cannot be achieved with high accuracy relying
on combinations of structure- and thermodynamic-derived features even with the aid of classical and state of the
art statistical learning methods.
We developed a procedure to predict responsive mutations with an accuracy as high as 87%: the method scores
the mutations by using a suitable position-specific substitution matrix. Our approach is of general applicability
since it does not require the knowledge of 3D-structure but relies only on the sequence.
Conclusions: Responsiveness to pharmacological chaperones depends on the structural/functional features of the
disease-associated protein, whose complex interplay is best reflected on sequence conservation by evolutionary
pressure. We propose a predictive method which can be applied to screen novel mutations of alpha galactosidase.
The same approach can be extended on a genomic scale to find candidates for therapy with pharmacological
chaperones among proteins with unknown tertiary structures.
Background
Pharmacological chaperone (PC) therapy has been
recently proposed as a promising strategy for the treat-
ment of some genetic diseases. PC therapy exploits small
molecules which can be administered orally, reach diffi-
cult tissues such as the brain and have low cost. The new
approach relies on an unexpected finding: some mole-
cules that at high dosage inhibit specific proteins, can, at
low dosage, restore their activities in cells. They act as
life jackets or chaperones for proteins that, although
retaining the essential residues needed for activity,
become unstable upon mutation and are degraded. These
proteins are able to fulfill their duty if they are given the
chance to survive long enough and get to the site where
they are needed.
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has produced a few drugs which are already in clinical
trials. The treatment of metabolic diseases with competi-
tive inhibitors as chemical chaperons at sub-inhibitory
intracellular concentrations was first proposed by Fan et al
in 1999 [1]. They presented evidence that administration
of Deoxy-galactonojirimycin (DGJ) at low concentration
effectively enhanced mutant lysosomal alpha-galactosidase
A [UNIPROT: AGAL_HUMAN] activities in lymphoblasts
from Fabry patients with R301Q or Q279E mutations.
Since then PC have been exploited for other lysosomal
storage disorders such as Gaucher [2], Pompe [3], Tay-
Sachs, Sandhoff [4], GM1 gangliosidosis [5,6], Niemann-
Pick [7,8] and for the stabilization of a variety of non
lysosomal proteins of medical interest such as the ATP
binding cassette (ABC) family of transporters, G-protein-
coupled receptors (GPCRs), tyrosinase, copper ATPase,
p53 and carnitine transporters [9,10].
Fabry disease (FD) is X-linked and relatively frequent,
1-9 in 100000 [ORPHANET: orpha324, OMIM: 30150].
Different mutations of the gene encoding AGAL result in
a wide phenotypic spectrum, with respect to age at onset,
rate of disease progression, severity of clinical manifesta-
tions. Mutations with low or absent residual AGAL activ-
ity are generally observed in the classic infantile form of
the disease. Patients with the late onset form of FD retain
some AGAL activity and are asymptomatic until adult
age when they develop cardiac and kidney problems.
Nonetheless, as pointed out by Schaefer et al “clinical
phenotype, age of onset and course of Fabry disease are
very variable, even within the same family, which makes
it difficult to define a genotype-phenotype relationship by
analysing individual patients “ [11]. Since the age of onset
can be late and its complications, cardiac manifestations,
stroke and chronic renal disease, are very similar to those
of other very common disorders, FD could have been
under diagnosed and an estimate as high as 1 in 3100 live
births has been put forward [12].
FD offers an interesting case for studying the potentiality
of PC because, since the pioneering work by Fan et al [1],
responsiveness to PC has been assessed for a huge number
of mutations, covering both early and late onset forms of
Fabry disease [13-15]. A relatively large proportion of
mutants, in particular among mutations associated with
the late onset form of FD, recover activity when treated
with DGJ. In this study, we correlated the responsiveness
to DGJ with specific properties of the mutant AGAL
sequences and developed a predictive protocol of general
applicability to spot mutations which respond to PC.
Results and Discussion
Classification of mutants
To try to correlate the properties of AGAL mutants
to their responsiveness to PC, we needed a set of
mutations as large as possible. DGJ has been tested on a
large proportion of AGAL mutants and we collected
data from three different papers which reported the
enzymatic activity for each mutation in the presence
and absence of DGJ and the activity of the wild-type
protein [13-15]. We gathered 96 different mutations in
total which had been tested for responsiveness to DGJ.
Responsiveness to DGJ is variable among mutations and
we needed a precise threshold to define a binary label.
We calculated the ratio between the activity of the
mutants in the presence of the drug and the reference
wild type activity measured in the absence of DGJ, for
each study. This data (+DGJ/wild × 100) and the appro-
priate references are reported in additional files 1 and 2.
We assigned responsiveness to two classes: 23 mutants
were considered responsive because they recover at least
50% of normal activity in the presence of DGJ and
73 were considered non responsive. This conservative
definition of responsiveness was adopted because the
clinical indication of GLA mutations associated with FD
is galactosidase activity less than 50% of the normal
mean value in plasma [16].
Structural characterization of mutants
Clinically important mutations can affect either the func-
tion or the structure of a protein: assessment of respon-
siveness to PC may depend critically on the correct
classification of mutations. The first step in our analysis
was the identification of the active site. For this purpose
we detected pockets on the surface of AGAL, pdb code
3GXT, with the program CASTP [17,18]. Among these
pockets we selected the one with the highest proportion of
atoms belonging to conserved amino acids. We preferred
this approach to direct identification of the residues in
contact with galactose or DGJ in the crystal structures of
the holo-enzyme [19-21].because galactose is a product of
the enzyme obtained after the hydrolysis of a much larger
substrate, globotriaosylceramide [22]. It might well be that
residues in contact with galactose or with its analogue
DGJ [19-21], represent only one part of the real active site.
The pocket with the highest proportion of conserved
amino acids includes four groups of amino acids: a)
D92, D93, C142, D170, R227, D231 (red in Figure 1),
residues completely conserved and associated with
mutations not responding to DGJ; b) Y207 (blue in
Figure 1), residue not conserved and associated with
mutations not responding to DGJ; c) E203, L206, S297
(yellow in Figure 1) residues conserved and not asso-
ciated with mutations tested with DGJ; d) W47, Y134,
K168 (green in Figure 1), residues not conserved and
not associated with mutations tested with DGJ. The
pocket overlaps the residues which bind galactose or
DGJ (D92, D93, K168, D170, E203, R227, D231) in the
crystal structure of AGAL [21].
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sive: this is expected because DGJ acts only on the stabi-
lity of the protein, and cannot restore the active site if
this has been damaged. They represent 12% of the total
number of non responsive mutations tested (Figure 1
and additional file 1).
The distance from the active site was also measured. Not
only mutations that occur in the active site pocket, but
also those close to it, tend to be non responsive (additional
file 1) whereas it is possible that mutation occurring quite
far from the DGJ binding site can be responsive to the
drug as observed for example for R363H and R363C
(R363 is coloured in purple in Figure 1). Indeed, distance
from active site correlates with the percentage of recov-
ered activity (+DGJ/wild × 100) with an r-value 0.16 and a
p-value 0.02 (additional file 1).
AGAL has 5 intra-chain disulphide bonds and any
tested mutation affecting a Cys involved in a bridge
results in a non responsive protein. This result is also
expected because disruption of a disulphide bond is
usually highly destabilising and can prevent correct pro-
tein folding. It is worth noticing that not all Cys in
AGAL are oxidised: Cys 90 and Cys 174 are not involved
i nad i s u l p h i d eb r i d g e ,b u tt h e yh a v en o tb e e nf o u n d
mutated in Fabry patients.
We then analysed other structure-derived independent
features.
Accessibilities to solvent of AGAL residues was mea-
sured both for the main chain atoms and the side chain
atoms of each residue and are reported in additional file
1. Side chain accessibility correlates with recovered per-
centage activity (+DGJ/wild × 100) with an r-value 0.14
and a p-value 0.02 whereas main chain accessibility does
not (additional file 1). We observe that mutations affect-
ing exposed residues have higher chances of being res-
cued by PC (Figure 2), but, this holds only if we
consider side chain accessibility. To assess the statistical
significance of the differences observed in Figure 2 we
performed the Wilcoxon rank sum test to reject the null
hypothesis of equal medians at the default 5% signifi-
cance level (P = 0.03).
We assigned each residue in AGAL to alpha helices,
beta sheets or others (data in additional file 1). By others
we mean any secondary structure different from alpha
Figure 1 The active site of human lysosomal alpha galactosidase. A monomer of human lysosomal alpha galactosidase is shown as a
ribbon. The pocket with the highest proportion of conserved amino acids includes four groups of amino acids: D92, D93, C142, D170, R227,
D231 (in red), completely conserved and associated with mutations not responding to DGJ; Y207 (in blue), not conserved and associated with
mutations not responding to DGJ; E203, L206, S297 (in yellow) conserved and not associated with mutations tested with DGJ; W47, Y134, K168
(in green) not conserved and not associated with mutations tested with DGJ. R363, the furthest site from active pocket where responsive
mutations, R363C and R363 H, have been observed is shown in purple.
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3-10, poly-proline, etc. Although some of these elements
might well be associated with functional roles or with
protein protein association [23,24], they are too rare in
A G A Ls t r u c t u r et ob eu s e f u lf o rp r e d i c t i v ep u r p o s e s .
The percentages of responding residues in alpha helices,
beta sheets and others reflect the percentage of respond-
ing mutations in the total data set suggesting that the
occurrence in a specific secondary structure element
does not determine the possibility of a mutation to be
sensitive to PC. Although residues in beta sheet tend to
respond when their side chains are exposed, paucity of
data in each class prevents a reliable statistical analysis
(data not shown).
We then used two programs, SDM [25,26] and
MUPRO [27], to assign a stability score to the mutants,
negative for unstable mutants and positive for stable
ones, which is analogous to the free energy difference
between a wild-type and mutant protein. The two pro-
grams provide independent assessment of protein stabi-
lity because they rely on completely different approaches
and do not reflect in any simple manner the structural
features already analysed. SDM requires the knowledge
of 3D-structure of AGAL and takes into account several
structural features to predict the effect of mutations on
protein stability. MUPRO does not require structural
information on AGAL structure since it learns with a
support vector machine method from the sequences
deposited in ProTherm [28] database, a collection of
numerical data of thermodynamic parameters for wild
type and mutant proteins, and applies the derived rules
to the sequence of an uncharacterised protein.
SDM scores correlate with the percentage of recovered
activity (+DGJ/wild × 100) with an r-value 0.23 and a
p-value 0.2 10
-3(additional file 1) whereas MUPRO
scores do not (additional files 1 and 2). Twenty per cent
of the mutations obtain a score lower than -3 with SDM
and all of these, but R363C, are non responsive. R363C
is responsive since it reaches 57% of wild type enzyme
activity upon treatment with DGJ, but gets a negative
score, -5.84, by SDM. On the other hand, a different
responsive mutation occurring at the same site, R363H,
gets a positive score, 0.11(additional file 1). Therefore,
SDM recognizes that a mutation of R363 can have a
small effect on protein stability and hence can be poten-
tially recoverable by PC, but over-estimates the damage
caused by the specific substitution with a Cys. We
ordered mutations by increasing SDM score and divided
them into four equally populated bins: Figure 3 panel A
shows that the percentage of responding mutations is
low at low SDM scores and increases progressively as
SDM score increases.
Similarly we sorted mutations by increasing MUPRO
score and divided them into 4 bins: non responding
mutations are more abundant in the bins associated
with low MUPRO scores (Figure 3 panel B) but differ-
ences among bins are not as large as with SDM. The
Pearson chi test confirms that the percentage of respon-
sive mutations in the bin associated with low SDM
scores (bin 1) is significantly different from expected
(p = 0.01) whereas that in the bin associated with low
MUPRO scores is not. On the other hand the percen-
tage of responsive mutations in the bin associated with
high MUPRO scores (bin 4) is significantly different
from expected (p = 0.04) whereas that in the bin asso-
ciated with high SDM scores is not.
We built box plots for the results obtained with the
two programs: differences between respondent and non
respondent mutations are more evident comparing the
first quartile for SDM (Figure 3 panel C) or the third
quartile for MUPRO (Figure 3 panel D). The Wilcoxon
rank sum test rejects the null hypothesis of equal med-
ians for SDM boxplots at the default 5% significance
level (P = 0.03). Regarding MUPRO, we cannot assess
the normal distribution of the two samples with suffi-
cient confidence. However, we observed that the first
quartile of SDM scores for non responding mutations
occurs at -3.14, a value very close to the threshold of -3
below which, as already discussed, mutations are non
responsive. On the other hand we observed that the
third quartile of MUPRO scores for responding muta-
tions occurs at -0.14 a value above which mutations are
mainly responsive (additional file 2).
Prediction of responsiveness
Analysis of AGAL structure reveals that three groups of
mutations, those affecting the active site, those affecting
disulphide bridges and those severely scored by SDM
Figure 2 Responsiveness to DGJ and solvent accessibility.
Occurrences of responsive or non responsive mutations in
accessible (blue bars) or non accessible (red bars) residues are
reported as percentage: we used a cut-off of 5.0% as a threshold of
side-chain solvent accessibility. Differences between percentage
shown in blue and red bars are statistically significant (p = 0.03).
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mutation which does not belong to any of these groups,
can be either responsive or non responsive. In order to
improve the usefulness of the model in patient therapy,
we would like to predict responsiveness to DGJ for any
AGAL mutation after having seen a number of training
examples and this is, in statistical sense, a typical super-
vised classification task. Mutants have been labelled as
respondent (23) or not respondent (73) and seven inde-
pendent features derived from the analysis of 3D-struc-
ture of the enzyme and two features associated with
their thermo-dynamic stability have been assigned to
each of them as described before. Our goal is to find a
mathematical function that given a set of features
returns the correct class of the mutation. We tested all
classification methods available in MATLAB-Arsenal
developed by Rong Yan [29], which represent a large
sample of all de facto standard classification algorithms.
We compared the results obtained with MATLAB-
Arsenal classifiers to those obtained with the ZeroR
classifier. ZeroR classifier simply predicts the majority
class in the training data. For example, if most of the
training data are non respondent, ZeroR will predict all
inputs as non respondent. Running ZeroR is necessary
for determining a baseline performance as a benchmark
for other learning schemes.
We found that although many structural derived fea-
tures, distance from active site, side chain accessibility,
SDM scores, disruption of disulphide bonds, correlate
with percentage recovered activity (+DGJ/wild × 100
please see additional file 1), they are not useful to pre-
dict responsive mutations with an accuracy, precision or
Figure 3 Responsiveness to DGJ and mutant stability. Mutants were divided into four equally populated bins (each including 25%
mutations) of increasing predicted stability. For each bin a blue bar shows the percentage of responding mutations, a red bar the percentage of
non responding ones. Panel A: bin 1 includes mutations with SDM scores ranging from -11.28 to -2.26; bin 2 from -2.26 to -0.86; bin 3 from -0.73
to 0.25; bin 4 from 0.25 to 3.65. Panel B: bin 1 includes mutations with MUPRO scores ranging from -2.46 to -1.25; bin 2 from -1.25 to -0.95; bin 3
from -0.95 to -0.60; bin 4 from -0.57 to 0.42. Bins with p = 0.01 or p = 0.04 are indicated with ** or * respectively. Box plots for the same data
are shown in panel C for SDM and in panel D for MUPRO: the difference between the medians of SDM scores associated with responsive
mutations and non responsive mutation is statistically significant (p = 0.03).
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The classifier which performed significantly better than
ZeroR is DecisionStump on MUPRO results, with 81%
accuracy versus 24% of the baseline. Prediction of
responsive mutations can be achieved with MUPRO
because it assigns the highest scores preferentially to
mutations which recover activity upon treatment with
PC (additional file 2).
MUPRO predicts protein stability relying only on
sequence information. This result encouraged us to rely
on sequence alone and try and do better than MUPRO
exploiting evolutionary conservation. In the first place
we scored mutations using Blosum62, a matrix which
considers only the pair of amino-acids involved regard-
less of the site where the mutation occurs. Performance
of DecisionStump with Blosum62 scores (74% accuracy)
is better than the baseline (24% accuracy), but much
lower than that obtainable with MUPRO scores (81%
accuracy). We decided to take into account the position
where mutations occur in the protein using position
specific substitution matrices (PSSM). PSSMs are built
with PSI-BLAST [30], a program that uses as an input a
set of homologous proteins, aligns the sequences and
calculates amino acid substitution scores separately for
each position in the multiple alignment. We carried out
three independent experiments: we collected a first set
of AGAL homologous proteins which includes very dis-
tant homologs with e-value as low as e-3, a second set
which includes only close homologs with e-value higher
than e-50 and a third set which includes only close
orthologs, excluding the sequences derived by gene
duplication. In fact, two paralogous lysosomal enzymes
alpha-galactosidase A (AGAL_HUMAN; EC 3.2.1.22)
and alpha-N-acetylgalactosaminidase (NAGAB_HU-
MAN; EC 3.2.1.49) exist in higher animals.
We run PSI_BLAST independently on the three sets
and obtained different PSSM. The scores obtained with
the PSSM built with close homologs of AGAL as well as
those obtained with far homologs and close orthologs
correlate with the percentage of recovered activity upon
treatment with DGJ (+DGJ/wild × 100) respectively with
r-value 0.44 and p-value <0.1 10
-3; r-value 0.44 and
p-value <0.1 10
-3; r-value 0.32 and p-value 0.2 10
-3.T h e
scores obtained with PSSMs were used as inputs for
DecisionStump to test their ability to predict responsive
mutations. The PSSM built aligning close homologs
(e-value <e-50) led to the best results: its performance
(87% accuracy) is better than that obtained with the
scores of MUPRO and, in particular, recall is much
higher (49% versus 30%) which means that less false
negatives are predicted (Table 1).
The approach we used to predict responsiveness to PC
is similar to that used by some programs to predict
disease-associated mutations: results obtained with Poly-
Phen [31], which are reported in additional file 2 were
used as inputs of DecisionStump classifier and allowed
prediction of AGAL PC responsive mutations with 75%
accuracy.
When developing a classifier, the numbers of respond-
ing mutations erroneously predicted as non responding
(FN) as well as non responding mutations erroneously
predicted as responding (FP) should be kept at a mini-
mum. Therefore precision (TP/TP+FP) and recall (TP/
TP+FN) are very useful to assess the performance of dif-
ferent methods. It is not surprising that precision and
recall are lower than accuracy (TP+TN/TP+TN+FP
+FN) in any case reported in Table 1 because correctly
predicted non responding mutations (TN) increase
accuracy but not precision and recall. Specific classes of
non responding mutations are identified by structural
analysis, and in general it is easier to predict TN than
TP. DecisionStump based on the scores of the PSSM
built with AGAL_HUMAN close homologs provides the
highest precision and recall in comparison with the
other tested methods (including PolyPhen). Nonetheless
it should be emphasized that, regrettably, false positives
and even more false negatives are predicted as implied
by the fact that precision and recall values are well
below 1 (Table 1).
Results obtained with sequence information alone do
not improve if structure derived information are added
as features for the classifiers in MATLAB-Arsenal [29]
(data not shown).
After this manuscript was submitted we became aware
of three new AGAL mutations [32,33], C52Y, Y216C
and G183A [32] which recover respectively <10%, 40%
and 65% activity upon treatment with PC. This report
offered us the opportunity for a test on mutations not
included in the development of the method. C52Y dis-
rupts a disulphide bonds and thus belongs to a class of
Table 1 Performance of prediction of DGJ responsiveness
by DecisionStump on sequence derived features
accuracy precision recall
zeroR 0.240 ± 0.003 0.239 ± 0.003 1 ± 0
MUPRO 0.811 ± 0.001 0.555 ± 0.091 0.302 ± 0.017
Blosm62 0.737 ± 0.005 0.183 ± 0.057 0.176 ± 0.069
Close_homologs 0.867 ± 0.001 0.666 ± 0.125 0.489 ± 0.102
Far_homologs 0.786 ± 0.026 0.463 ± 0.033 0.364 ± 0.027
Close_orthologs 0.812 ± 0.001 0.477 ± 0.097 0.347 ± 0.062
PolyPhen 0.745 ± 0.028 0.179 ± 0.151 0.108 ± 0.058
Mutations were scored by the trivial classifier ZeroR to set a baseline, by
MUPRO, by Bloum62 or by PSSMs derived by sets of sequences which include
distant homologs (e-value > e-3), close homologs (e-value > e-50) or close
orthologs (e-value > e-13).
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a negative score by SDM, -1.582, by MUPRO, -1.37 and
by PSSM, -5, and is correctly predicted as non respon-
sive. Y216C according to our conservative definition is
non responsive since it does not reach 50% of wild type
activity: it does not belong to the three groups of muta-
tions which are definitely unrecoverable (i.e. it does not
belong to the active site, it does not disrupt disulphide
bonds, it is not severely destabilizing), but it gets a nega-
tive score -2.319 by SDM, -1.16 by MUPRO and -3 by
PSSM and is correctly predicted as non responsive.
G183A does not belong to the three groups of muta-
tions which are definitely unrecoverable, it gets a posi-
tive score 2.33 by SDM and a negative score, -1.47, by
MUPRO and is erroneously predicted as non responsive,
because of a PSSM score -2. The PSSM score -2, is
immediately below the threshold set by the classifier to
minimize false negatives and false positives. Indeed, this
score represents a twilight zone where the recovered
activity (+DGJ/wild x100) of mutations can vary from
0% to 100% and for 19% of mutations is above 50%. We
observed that with a few exceptions, responsive muta-
tions erroneously predicted by the classifier (FN) either
h a v eap o s i t i v eS D Ms c o r e( a si ti st h ec a s ef o rG 1 8 3 A )
or have a solvent exposed side chain.
Conclusions
Mutations which occur at non exposed sites or in the
a c t i v ep o c k e ta r el i k e l yt ob en o nr e s p o n s i v et oD G Ja s
well as those compromising stability, but the complex
interplay between functional and structural features on
responsiveness makes difficult their exploitation for pre-
dictive purposes. However, the same features strongly
tune evolutionary pressure at different sites in a protein.
For this reason methods based on conservation alone can
be exploited to predict responsiveness to PC: addition of
structural features does not improve prediction because
by measuring conservation we have already, implicitly,
taken them into account. It is generally accepted that dis-
ease causing mutations are more frequent at conserved
sites whereas non disease polymorphisms prevail at vari-
able site and we demonstrated that this holds also for
non responsive and responsive mutations. The score
assigned to mutation by a PSSM takes into account the
degree of conservation of the wild type amino acid in
homologous sequences and the specific substitution that
is introduced: if the new amino-acid is present in homo-
logous species a less negative score is obtained. We have
shown that high PSSM scores are associated with respon-
dent mutations whereas low PSSM scores are associated
with non respondent mutations and that this property
can be exploited for predictions. It is not trivial, however
the effect of the inclusion of homologs with a low
percentage of identity in the construction of the PSSMs
for at least three reasons:
1) sites that are critical for the function of enzymes
in mammals or in metazoa might have varied in evo-
lutionary distant species and many compensative
mutations might have arisen
2) the inclusion of proteins in the twilight zone
necessarily raise the possibility of introducing false
homologs.
3) The inclusion paralogs can hinder functional
important sites.
Our analysis proves that the choice of homologs for the
construction of the PSSM is critical: paralogs can be
included, but too distant homologs must be excluded.
O u rm e t h o dc a nb ea p p l i e dt o predict PC responsive-
ness of novel and as yet untested mutations of alpha galac-
tosidase. This is feasible and useful because a very high
number of natural missense mutations have been found
for AGAL, a middle sized protein of 429 aa: 146 are listed
in Uniprot/Swissprot [34], 256 in the public version of
Hgmd [35]. This figure might well rise if Fabry disease has
been under diagnosed as it seems to be the case. In parti-
cular it can be predicted that new mutations associated
with the late on-set form of the diseases, that are the most
likely be respondent to DGJ will be found. In order to
make a projection of the results obtainable with our
method, we tested 299 mutations of AGAL listed in Uni-
protSwissprot and HGMD and we estimated that 40
mutations as yet untested with PC are likely to respond.
When a AGAL mutation not already tested in vitro
for responsiveness to DGJ is encountered, clinicians can
direct Fabry patients towards the therapy more likely to
ameliorate their phenotype: a high PSSM score should
suggest a beneficial effect of DGJ whereas a low PSSM
score should suggest caution and direct towards enzy-
matic replacement [36,37]. DecisionStump classifier sets
a threshold to minimize false negatives and false posi-
tives and allows, if required by clinicians, a clear cut
indication for therapeutic intervention.
Although PC therapy will not substitute other thera-
pies for FD such as enzymatic replacement [36,37], our
results reinforce the idea that, at least in principle, these
novel drugs, affordable and suitable for oral administra-
tion, have vast applicability.
Our approach to find candidates for PC therapy is not
limited to alpha galactosidase, but can be extended on a
genomic scale among proteins with unknown tertiary
structures. Moreover due to the low cost associated
with an in silico screening it meets regulators which
look for ways to make it easier and cheaper for drug
companies to develop treatments for rare diseases.
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Construction of data set
A list of AGAL mutations was created and to each one
a label, 1 for responsive and 0 for non responsive ones,
was added. Original data of enzymatic activity in the
presence or in the absence of DGJ were taken from
three different papers [13-15]. The data is redundant
since responsiveness of some mutants have been ana-
lysed by more than one group and we obtained in total
96 different tested mutations. In additional file 1 and 2
we calculated the percentage recovered activity, that is
activity of the mutant in the presence of DGJ divided by
the activity of wild type AGAL multiplied by 100
(+DGJ/wild × 100), and the appropriate reference.
The reference wild type activity, measured in the
absence of DGJ was obtained for each mutation from
the appropriate paper.
Mutants are responsive if in the presence of DGJ
recover at least 50%, of normal activity and non respon-
sive in the other case.
Construction of PSSMs
We identified three sets of sequences: the first includes
163 homologs of AGAL with e-value < e-3 and identity
ranging from 98% to 20% from GenBank CDS Transla-
tions, PDB, SwissProt, PIR, PRF; the second includes 13
homologs with e-value <e-50 and identity ranging from
95% to 30% from Uniprot/Swissprot; the third includes
15 orthologs with evalue e < e-150 and identity ranging
from form 98%to 64% from translated GenBank, EMBL,
DDBJ.
BLASTPGP (BLASTP2.2.18) in PSI-BLAST mode was
used on each set flagging on the output of a checkpoint
file (PSSM matrix) and selecting one of the following
scoring matrices: Blosum80, Blosum62, Blosum45,
Pam70 or Pam30.
Fifteen different PSSM were obtained and exploited in
a second round of BLASTPGP to calculate net scores
for AGAL mutants (mutant score PSSM(i)-Agal_wild
score PSSM(i)) [30].
With any set of homologous proteins the best
results (Table 1) were obtained selecting Blosum62
(BLASTPGP -d Blosum62); complete results for all
PSSM are given in additional file 3.
The percentage of identical amino acids was also
assessed aligning AGAL with 13 homologs with e-value
<e-50 and identity ranging from 95% to 30% from Uni-
prot/Swissprot. At each position in the alignment we
count the number of sequences sharing the same amino
acid of AGAL and we divided by the total number of
sequences in the alignment. Results in percentage are
included in additional files 1 and 2.
Active site identification
We detected active site residues with a procedure of
general applicability inspired by the paper published by
Dundas et al [17].
We detected cavities in AGAL structure, 3GXT, with
the program CASTP [17,18] and we selected the pocket
with the highest proportion of atoms belonging to con-
served amino acids. To identify conserved residues we
aligned 13 homologs with e-value <e-50 and identity
ranging from 95% to 30% from Uniprot/Swissprot At
each position in the alignment we count the number of
sequences sharing the same amino acid of AGAL and
we divided by the total number of sequences in the
alignment.
All the residues lining that pocket, irrespective of their
conservation, were considered to potentially belong to
the active site.
Prediction of mutants stability
MUPRO1.1 [27] was kindly provided by Dr J. Cheng: we
run the program locally using as inputs only AGAL
sequence, the position affected by the mutation, the ori-
ginal and the mutant amino-acid.
Models of all AGAL mutants are constructed using as
template 3GXT [21] with the program ANDANTE
which predicts side-chain conformations by use of envir-
onment-specific substitution probabilities and a high-
quality rotamer library [38].
The asymmetric unit in 3GXT [21] contain the
dimeric enzyme and monomers are not fully super-
imposable as expected. For this reason each mutation
was built in both chains.
SDM [25,26] uses a set of conformationally con-
strained environment-specific substitution tables and
calculates the difference in the stability scores for the
folded and unfolded state of each mutant and the wild-
type protein. It uses as inputs the mutants generated
with ANDANTE and the structure of the wild type
enzyme.
The programs SDM and ANDANTE were kindly pro-
vided by T. Blundell and collaborators.
Accessibility and secondary structure
Residue accessibility was calculated using PSA v2.0 (L.
Cheng, unpublished) which uses the rolling probe algo-
rithm [39]. For the threshold of solvent accessibility, we
used a cut-off of 5.0% relative total side-chain or main
chain accessibility.
The numbers of responsive or non responsive muta-
tions with accessible side chain was divided by the total
number of mutations with accessible side chain and
multiplied by 100. In a similar way it was calculated the
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with non accessible side chain.
The program PSA was kindly provided by T. Blundell
and collaborators.
We assigned each residue in the wild type AGAL
structure 3GTX to alpha helices, beta sheets or other
with the program SEGNO [40].
Supervised classification
We tested all classification methods available in
MATLAB-Arsenal developed by Rong Yan [29] The accu-
racy of the methods has been assessed using tenfold cross
validation. This means that we have divided all mutants
for which the responsiveness is known in ten folds. At
each step, one fold has been sorted out and used as a test.
The remaining mutants have been used to train the classi-
fier. In total, tests were repeated thirty times and values
h a v eb e e nt a k e no na v e r a g e .R e s u l t sa r ee x p r e s s e da s
mean accuracy ((TP+TN)/TOT), which represents the
mean percentage of correctly classified instances, precision
(TP/(TP+FP)) and recall (TP/(TP+FN)).
When analysing structural features, mutations occur-
ring on different chains had to be taken into account
and therefore DecisionStump used 96 × 2 input data,
when analysing sequence derived features, i.e. MUPRO,
B l o s u m6 2 ,P S S M ss c o r e so rP o l y P h e nP S I Cs c o r ed i f -
ferences, DecisionStump used 96 input data.
Statistical analysis
All statistical analyses were carried out with MATLAB.
To calculate the correlations and p values shown in
additional files 1 and 2 we used corrcoef: this function
returns a matrix R of correlation coefficients and a
matrix of p-values for testing the hypothesis of no cor-
relation. Each p-value is the probability of getting a cor-
relation as large as the observed value by random
chance, when the true correlation is zero.
To analyse the data shown in Figure 2 and 3 (panel C,D)
we carried out the Wilcoxon test with the function rank-
sum. This function performs a two-sided rank sum test of
the null hypothesis that data are independent samples from
identical continuous distributions with equal medians,
against the alternative that they do not have equal medians.
To evaluate the influence of solvent accessibility on
PC responsiveness and to assess the statistical signifi-
cance of the differences observed and differences
expected by chance, we took a random sample of 30%
in both exposed and non exposed population and
counted the number of responding and non responding
mutations. We repeated the randomization 100 times
and calculated the differences between the percentage of
responsive mutations in exposed and non exposed sites
and the differences between the percentage of non
responsive mutations in exposed and non exposed sites.
To test the hypothesis that distribution of Mupro and
SDM scores among responsive and non responsive
mutations is different from what could be expected by
chance (Figure 3 panel A and B), we run the chi2test.
We ordered mutations by increasing SDM (or MUPRO)
score and divided them into four equally populated bins.
T h ef u n c t i o nu s e da si n p u t st h ep e r c e n t a g e so b s e r v e d
and expected in each bin and returned chi2 values and
the associated p values.
Additional material
Additional file 1: Structure-based analysis of human lysosomal
alpha galactosidase. Original data of enzymatic activity in the presence
or in the absence of DGJ were taken from three different papers:
Benjamin et al 2009, Shin et al 2008, Shimotori et al 2008 [13-15].
Percentage recovered activity, that is activity of the mutant in the
presence of DGJ divided by the activity of wild type AGAL multiplied by
100 (+DGJ/wild × 100) is reported for each mutation with the
appropriate reference. Responsiveness is set to 1 if (+DGJ/wild × 100)
≥50. The table contains SDM scores (SDM), % main chain accessibility
(mc_access), % side chain accessibility (sc_access). Occurrence in alpha
helix (alpha), beta strands (beta), other secondary structures (other),
active site (as) or sites involved in disulphide bridges (ss) is indicated by
1. Distance from active site (as) is measured in angstrom, identity in close
homologs (% ident) as percentage. The data were used as an input to
calculate the correlation coefficients (R) and the p-values that are shown
in a separate sheet (correlation and p-values). Each p-value is the
probability of getting a correlation as large as the observed value by
random chance, when the true correlation is zero.
Additional file 2: Sequence-based analysis of human lysosomal
alpha-galactosidase. Original data of enzymatic activity in the presence
or in the absence of DGJ were taken from three different papers:
Benjamin et al 2009, Shin et al 2008, Shimotori et al 2008[13-15]
Percentage recovered activity, that is activity of the mutant in the
presence of DGJ divided by the activity of wild type AGAL multiplied by
100 (+DGJ/wild × 100) is reported for each mutation with the
appropriate reference. Responsiveness is set to 1 if (+DGJ/wild × 100)
≥50. F_H, C_H and C_O indicate net scores derived from sets of
sequences which include distant homologs (e-value > e-3), close
homologs (e-value > e-50) or close orthologs (e-value > e-13)
respectively. On each set of sequences PSI-BLAST was run selecting
different scoring matrices, Blosum 45, Blosum62, Blosum80, Pam30,
Pam70, therefore BL stands for Blosum, PM for Pam. Stability scores
(MUPRO), Blosum62 scores (BL62), identity in close homologs (% ident),
POLYPHEN predictions are also reported. The data were used as an input
to calculate the correlation coefficients (R) and the p-values that are
shown in a separate sheet (correlation and p-values). Each p-value is the
probability of getting a correlation as large as the observed value by
random chance, when the true correlation is zero.
Additional file 3: Performance of prediction of DGJ responsiveness
by DecisionStump on sequence derived features. Mutations were
scored by PSSMs derived by sets of sequences which include distant
homologs (e-value > e-3), close homologs (e-value > e-50) or close
orthologs (e-value > e-13). On each set of sequences PSI-BLAST was run
selecting different scoring matrices, Blosum 45, Blosum62, Blosum80,
Pam30, Pam70.
Abbreviations
DGJ: Deoxy-galactonojirimycin; FD: Fabry disease; FN: false negative; FP: false
positive; PC: pharmacological chaperone; PSSM: position specific substitution
matrix; TP: true positive; TN: true negative.
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